Wound Management Technologies introduces CellerateRX wound care collagen product in South Africa

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) is pleased to announce the sales expansion of its advanced wound care collagen product, CellerateRX, into South Africa.  With EWA Government Systems and Spiramed (Pty) Ltd., the Company has obtained the registration of the product in the region and has also obtained the necessary NAPPI codes, which are a pre-requisite for any billable health product in South Africa.  In addition, CellerateRX® is registered with various South African insurance companies and is an authorized product for reimbursement. The CellerateRX® products will be distributed by Spiramed (Pty) Ltd.

Wound Management Technologies' subsidiary, Wound Care Innovations, LLC, has the exclusive world wide distribution rights to CellerateRX® and has a representative agreement with EWA Government Systems to engage CellerateRX® distributors in Africa and other international markets.

"We are pleased to be working with Wound Care Innovations, LLC and Spiramed (Pty) Ltd. to introduce CellerateRX® to the African market," stated Lynn Adcock, Director of Africa Strategic Planning, EWA Government Systems, Inc.  "We have received positive responses from multiple African countries with the clinical use of this product."

"The recurring worldwide acceptance of CellerateRX® evidenced by our recent expansion into Central America and now South Africa, shows that our international sales efforts are well placed and that CellerateRX® has unique benefits in wound care," states Cathy Bradshaw, President of Wound Care Innovations.    "EWA has worked diligently to get the CellerateRX® products into this market and we look forward to continued market expansion with them."

CellerateRX® is FDA approved for market for all acute and chronic wounds except 3rd degree burns.